French antibiotics player Deinove has inked a licence option agreement with Redx Pharma plc concerning a new class of synthetic preclinical topoisomerase blockers to treat infections caused by Gram-negative ESKAPE pathogens.
The German Bioeconomy Council said policymakers would risk Germany’s leadership in bioeconomy if they don’t capitalise on new technology options resulting from the ongoing merger of digital and bio-technologies.
https://european-biotechnology.com/wp-content/uploads/2024/04/Carbios-Production.png565843Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-21 08:28:212018-03-21 08:28:21Bioeconomy: Germany to lose pole position
Hansa Medical AB, a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that the board of directors have appointed Søren Tulstrup as new President and CEO of Hansa Medical effective today March 20, 2018.
https://european-biotechnology.com/wp-content/uploads/2024/04/SorenTulstrop.jpg400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-03-20 15:23:322018-03-20 15:23:32Søren Tulstrup appointed CEO of Hansa Medical
VEGF blocker Eylea (aflibercept), which is co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006, has met the 24-week primary endpoint of the pivotal Panorama Phase III trial.
https://european-biotechnology.com/wp-content/uploads/2024/04/DME_NEI_tg.jpg621975Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-20 11:21:342018-03-20 11:21:34Eylea met Phase III endpoint in diabetic retinopathy
H. Lundbeck A/S has announced it will acquire Dutch Prexton Therapeutics B.V., a one-programme company developing the allosteric metabotropic glutamate receptor subtype 4 (mGluR4) modulator foliglurax (PXT002331) in Parkinson’s Disease.
Dunn Labortechnik presents a special product range from Porvair Sciences for sample preparation and improved productivity in drug discovery: evaporator, manifold, plate sealer and plates.
https://european-biotechnology.com/wp-content/uploads/2024/04/Dunn_Porvair_Drug_discovery.jpg450800Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2018-03-16 09:36:112024-04-02 15:51:43Equipment, plates and seals from Porvair Sciences for automation in drug discovery
Researchers from Sweden, Switzerland, France, Italy, and Germany report that expression of a post-stroke factor boost arterial plaque formation. The identification of the new target might open up an avenue to prevent embolism and further complications in stroke patients.
At the 11th Berlin Conference, Novo Holdings outlined details of a new €135m investment fund launched to push the development of new drug classes urgently needed to fight antimicrobial resistance. European Biotechnology editors were the first to talk with Aleks Engel, Partner at Novo Holdings, and George Griffin, Chair of the Repair Impact Fund’s Scientific Advisory Board, about the construction and the goal of the fund.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb2018springaleksengel.jpg450800Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-15 12:37:482024-04-02 16:21:28Making an impact on AMR R&D
Researchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist variation in histopathological diagnosis and resulted in a change of diagnoses in up to 12% of prospective cases.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-15 07:26:432018-03-15 07:26:43Algorithm tracks cancer type down to methylation pattern
The tremendous success of last year’s BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised as a worthy successor.
https://european-biotechnology.com/wp-content/uploads/2024/04/2018_03_14_BIOEuropeSpring.jpg540960Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-03-14 08:39:272018-03-14 08:39:27Business as usual in Amsterdam
Deinove to licence antibiotic leads form RedX Pharma
Latest NewsFrench antibiotics player Deinove has inked a licence option agreement with Redx Pharma plc concerning a new class of synthetic preclinical topoisomerase blockers to treat infections caused by Gram-negative ESKAPE pathogens.
Bioeconomy: Germany to lose pole position
Latest NewsThe German Bioeconomy Council said policymakers would risk Germany’s leadership in bioeconomy if they don’t capitalise on new technology options resulting from the ongoing merger of digital and bio-technologies.
Søren Tulstrup appointed CEO of Hansa Medical
AppointmentsHansa Medical AB, a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that the board of directors have appointed Søren Tulstrup as new President and CEO of Hansa Medical effective today March 20, 2018.
Eylea met Phase III endpoint in diabetic retinopathy
Latest NewsVEGF blocker Eylea (aflibercept), which is co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006, has met the 24-week primary endpoint of the pivotal Panorama Phase III trial.
Lundbeck acquiring Prexton in €905m deal
Latest NewsH. Lundbeck A/S has announced it will acquire Dutch Prexton Therapeutics B.V., a one-programme company developing the allosteric metabotropic glutamate receptor subtype 4 (mGluR4) modulator foliglurax (PXT002331) in Parkinson’s Disease.
Equipment, plates and seals from Porvair Sciences for automation in drug discovery
ProductsDunn Labortechnik presents a special product range from Porvair Sciences for sample preparation and improved productivity in drug discovery: evaporator, manifold, plate sealer and plates.
Stroke alarmin spurs further embolies
Latest NewsResearchers from Sweden, Switzerland, France, Italy, and Germany report that expression of a post-stroke factor boost arterial plaque formation. The identification of the new target might open up an avenue to prevent embolism and further complications in stroke patients.
Making an impact on AMR R&D
BackgroundAt the 11th Berlin Conference, Novo Holdings outlined details of a new €135m investment fund launched to push the development of new drug classes urgently needed to fight antimicrobial resistance. European Biotechnology editors were the first to talk with Aleks Engel, Partner at Novo Holdings, and George Griffin, Chair of the Repair Impact Fund’s Scientific Advisory Board, about the construction and the goal of the fund.
Algorithm tracks cancer type down to methylation pattern
Latest NewsResearchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist variation in histopathological diagnosis and resulted in a change of diagnoses in up to 12% of prospective cases.
Business as usual in Amsterdam
Latest NewsThe tremendous success of last year’s BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised as a worthy successor.